Optimizing the management of chronic obstructive pulmonary disease-reducing the risk of adverse cardiopulmonary event

doi:10.19983/j.issn.2096-8493.20230103

Abstract

CLC Number:

R563
R54

Chen Haijie, Chen Yahong. Optimizing the management of chronic obstructive pulmonary disease-reducing the risk of adverse cardiopulmonary event[J]. Journal of Tuberculosis and Lung Disease , 2023, 4(5): 337-341. doi: 10.19983/j.issn.2096-8493.20230103

References 48

[1]	Fang L, Gao P, Bao H, et al. Chronic obstructive pulmonary disease in China: a nationwide prevalence study. Lancet Respir Med, 2018, 6(6):421-430. doi:10.1016/S2213-2600(18)30103-6. pmid: 29650407
[2]	Zhu B, Wang Y, Ming J, et al. Disease burden of COPD in China: a systematic review. Int J Chron Obstruct Pulmon Dis, 2018, 27(13):1353-1364. doi:10.2147/COPD.S161555.
[3]	Mannino DM, Higuchi K, Yu TC, et al. Economic Burden of COPD in the Presence of Comorbidities. Chest, 2015, 148(1):138-150. doi:10.1378/chest.14-2434. pmid: 25675282
[4]	André S, Conde B, Fragoso E, et al. COPD and Cardiovascular Disease. Pulmonology, 2019, 25(3):168-176. doi:10.1016/j.pulmoe.2018.09.006. pmid: 30527374
[5]	Chen W, Thomas J, Sadatsafavi M, et al. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med, 2015, 3(8):631-639. doi:10.1016/S2213-2600(15)00241-6. pmid: 26208998
[6]	Ställberg B, Janson C, Larsson K, et al. Real-world retrospective cohort study ARCTIC shows burden of comorbidities in Swedish COPD versus non-COPD patients. NPJ Prim Care Respir Med, 2018, 28(1):33. doi:10.1038/s41533-018-0101-y.
[7]	Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest, 2005, 128(4):2640-2646. doi:10.1378/chest.128.4.2640. pmid: 16236937
[8]	Dalal AA, Shah M, Lunacsek O, et al. Clinical and economic burden of patients diagnosed with COPD with comorbid cardiovascular disease. Respir Med, 2011, 105(10):1516-1522. doi:10.1016/j.rmed.2011.04.005. pmid: 21684731
[9]	Natali D, Cloatre G, Hovette P, et al. Screening for comorbidities in COPD. Breathe (Sheff), 2020, 16(1):190315. doi:10.1183/20734735.0315-2019.
[10]	Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis, 2018, 12:1753465817750524. doi:10.1177/1753465817750524.
[11]	Brassington K, Selemidis S, Bozinovski S, et al. New frontiers in the treatment of comorbid cardiovascular disease in chronic obstructive pulmonary disease. Clin Sci (Lond), 2019, 133(7):885-904. doi:10.1042/CS20180316. pmid: 30979844
[12]	Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax, 2004, 59(7):574-580. doi:10.1136/thx.2003.019588. pmid: 15223864
[13]	Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J, 2009, 33(5):1165-1185. doi:10.1183/09031936.00128008. pmid: 19407051
[14]	Calverley PM, Scott S. Is airway inflammation in chronic obstructive pulmonary disease (COPD) a risk factor for cardiovascular events? COPD, 2006, 3(4):233-242. doi:10.1080/15412550600977544. pmid: 17361504
[15]	Tousoulis D, Papageorgiou N, Androulakis E, et al. Fibrinogen and cardiovascular disease: genetics and biomarkers. Blood Rev, 2011, 25(6):239-245. doi:10.1016/j.blre.2011.05.001. pmid: 21652129
[16]	Langer D, Ciavaglia CE, Neder JA, et al. Lung hyperinflation in chronic obstructive pulmonary disease: mechanisms, clinical implications and treatment. Expert Rev Respir Med, 2014, 8(6):731-749. doi:10.1586/17476348.2014.949676.
[17]	Barr RG, Bluemke DA, Ahmed FS, et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med, 2010, 362(3):217-227. doi:10.1056/NEJMoa0808836.
[18]	Casanova C, Cote C, de Torres JP, et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2005, 171(6):591-597. doi:10.1164/rccm.200407-867OC.
[19]	Gilbert JC, Glantz SA. Determinants of left ventricular filling and of the diastolic pressure-volume relation. Circ Res, 1989, 64(5):827-852. doi:10.1161/01.res.64.5.827. pmid: 2523260
[20]	Rossi A, Aisanov Z, Avdeev S, et al. Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. Respir Med, 2015, 109(7):785-802. doi:10.1016/j.rmed.2015.03.010. pmid: 25892293
[21]	Ball MK, Waypa GB, Mungai PT, et al. Regulation of hypoxia-induced pulmonary hypertension by vascular smooth muscle hypoxia-inducible factor-1α. Am J Respir Crit Care Med, 2014, 189(3):314-324. doi:10.1164/rccm.201302-0302OC.
[22]	Tuder RM, Yun JH, Bhunia A, et al. Hypoxia and chronic lung disease. J Mol Med (Berl), 2007, 85(12):1317-1324. doi:10.1007/s00109-007-0280-4.
[23]	Goudis CA, Konstantinidis AK, Ntalas IV, et al. Electrocardiographic abnormalities and cardiac arrhythmias in chronic obstructive pulmonary disease. Int J Cardiol, 2015, 199:264-273. doi:10.1016/j.ijcard.2015.06.096. pmid: 26218181
[24]	Laratta CR, van Eeden S. Acute exacerbation of chronic obstructive pulmonary disease: cardiovascular links. Biomed Res Int, 2014, 2014:528789. doi:10.1155/2014/528789.
[25]	Bhatt SP. Cardiac Considerations in Chronic Lung Disease. Berlin: Springer, 2020. doi:10.1007/978-3-030-43435-9.
[26]	Agustí A, Celli BR, Criner GJ, et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Eur Respir J, 2023, 61(4):2300239. doi:10.1183/13993003.00239-2023.
[27]	Cazzola M, Calzetta L, Matera MG, et al. Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients. Respir Med, 2015, 109(8):1019-1025. doi:10.1016/j.rmed.2015.05.021. pmid: 26111914
[28]	Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation, 2006, 113(19):2335-2362. doi:10.1161/CIRCULATIONAHA.104.482570. pmid: 16702488
[29]	孙永昌. 一呼一吸总关心. 中华结核和呼吸杂志, 2019, 42(11):804-805. doi:10.3760/cma.j.issn.1001-0939.2019.11.002.
[30]	Horita N, Nagashima A, Kaneko T. Long-Acting β-Agonists (LABA) Combined With Long-Acting Muscarinic Antagonists or LABA Combined With Inhaled Corticosteroids for Patients With Stable COPD. JAMA, 2017, 318(13):1274-1275. doi:10.1001/jama.2017.11903. pmid: 28973232
[31]	Hohlfeld JM, Vogel-Claussen J, Biller H, et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir Med, 2018, 6(5):368-378. doi:10.1016/S2213-2600(18)30054-7. pmid: 29477448
[32]	Cazzola M, Rogliani P, Calzetta L, et al. Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. Eur Respir J, 2018, 52(6):1801586. doi:10.1183/13993003.01586-2018.
[33]	中华医学会呼吸病学分会慢性阻塞性肺疾病学组,《慢性阻塞性肺疾病合并心血管疾病诊治管理专家共识》撰写组. 慢性阻塞性肺疾病合并心血管疾病诊治管理专家共识. 中华结核和呼吸杂志, 2022, 45(12):1180-1191. doi:10.3760/cma.j.cn112147-20220505-00380.
[34]	Jing X, Li Y, Xu J. Risk of Cardiovascular Events Associated with Inhaled Corticosteroid Treatment in Patients with Chronic Obstructive Pulmonary Disease: A Meta-Analysis. Can Respir J, 2018, 2018:7097540. doi:10.1155/2018/7097540.
[35]	Lipson DA, Barnhart F, Brealey N, et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med, 2018, 378(18):1671-1680. doi:10.1056/NEJMoa1713901.
[36]	Rabe KF, Martinez FJ, Ferguson GT, et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. N Engl J Med, 2020, 383(1):35-48. doi:10.1056/NEJMoa1916046.
[37]	Baker JG, Wilcox RG. β-Blockers, heart disease and COPD: current controversies and uncertainties. Thorax, 2017, 72(3):271-276. doi:10.1136/thoraxjnl-2016-208412. pmid: 27927840
[38]	Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2005, 2005(4): CD003566. doi:10.1002/14651858.CD003566.
[39]	Etminan M, Jafari S, Carleton B, et al. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulm Med, 2012, 12:48. doi:10.1186/1471-2466-12-48. pmid: 22947076
[40]	Rutten FH, Zuithoff NP, Hak E, et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med, 2010, 170(10):880-887. doi:10.1001/archinternmed.2010.112. pmid: 20498416
[41]	Lipworth B, Skinner D, Devereux G, et al. Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease. Heart, 2016, 2(23):1909-1914. doi:10.1136/heartjnl-2016-309458.
[42]	Wu J, Sin DD. Improved patient outcome with smoking cessation: when is it too late? Int J Chron Obstruct Pulmon Dis, 2011, 6:259-267. doi:10.2147/COPD.S10771.
[43]	Zhang J, Ou JX, Bai CX. Tobacco smoking in China: prevalence, disease burden, challenges and future strategies. Respirology, 2011, 16(8):1165-1172. doi:10.1111/j.1440-1843.2011.02062.x. pmid: 21910781
[44]	McCarthy B, Casey D, Devane D, et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2015, 2015(2): CD003793. doi:10.1002/14651858.
[45]	Spruit MA, Burtin C, De Boever P, et al. COPD and exercise: does it make a difference? Breathe (Sheff), 2016, 12(2):38-49. doi:10.1183/20734735.003916.
[46]	Gale NS, Duckers JM, Enright S, et al. Does pulmonary rehabilitation address cardiovascular risk factors in patients with COPD? BMC Pulm Med, 2011, 11(20):1-7. doi:10.1186/1471-2466-11-20.
[47]	Huang CL, Nguyen PA, Kuo PL, et al. Influenza vaccination and reduction in risk of ischemic heart disease among chronic obstructive pulmonary elderly. Comput Methods Programs Biomed, 2013, 111(2):507-511. doi:10.1016/j.cmpb.2013.05.006.
[48]	Marra F, Zhang A, Gillman E, et al. The protective effect of pneumococcal vaccination on cardiovascular disease in adults: A systematic review and meta-analysis. Int J Infect Dis, 2020, 99(1):204-213. doi:10.1016/j.ijid.2020.07.038.

Optimizing the management of chronic obstructive pulmonary disease-reducing the risk of adverse cardiopulmonary event

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 48

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zeng Wenmei, Wu Sulong, Liu Zhuofan, Yuan Long, Chen Bilin, Rong Yan. Analysis of all-night evaluation indexes and predictors of cardiovascular risk in patients with obstructive sleep apnea-hypopnea syndrome [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 1-7.
[2]	Yang Yarui, Guo Xujun, Wei Wei, He Juan, Li Shengbin, Zhong Tao, Gao Wanling, Liu Shoujiang, Liu Shengyuan. Awareness and factors associated with chronic obstructive pulmonary disease among permanent residents aged ≥40 years old in Nanshan District, Shenzhen [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(6): 517-525.
[3]	. [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(6): 597-600.
[4]	Yunnan Provincial Clinical Medical Center for Infectious Disease, Professional Committee of Respiratory Medicine of Yunnan Hospital Association, Professional Committee of Early Diagnosis and Treatment of Pulmonary Nodules of Kunming Medical Association. Expert consensus on standardized diagnosis and treatment of pulmonary nodules [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(5): 388-397.
[5]	Yuan Lirong, Yang Qinglong, Li Yuling, Li Lin, Deng Shasha, Li Shuhua. Effect of computerized cognitive behavioral therapy in the management of symptom cluster in patients with chronic obstructive pulmonary disease: a randomized controlled trial [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(5): 476-483.
[6]	Zhao Ruina, Li Shuhua, Cui Xiaohong, Gong Qiaoqiao, Pei Junli, Yuan Lirong. Distribution characteristics and influencing factors of pathogens in ventilator associated pneumonia [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(4): 305-310.
[7]	. [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(3): 187-190.
[8]	Wang Lin, Zhang Zinan. Current status and prospects of pulmonary rehabilitation in patients with chronic obstructive pulmonary disease [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(3): 191-196.
[9]	Zheng Xiaoxia, Zhu Xiaoxiao, Wu Yifan, Gu Fen. The correlation between symptom burden and quality of life in patients with chronic obstructive pulmonary disease [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(3): 207-211.
[10]	Pan Qiong, Tian Yayuan, Tong Fei. Effect of early limb active exercise on incidence of pulmonary embolism among patients received lung cancer surgery [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(3): 212-218.
[11]	Zhu Xiaoxiao, Tian Yayuan, Wang Pengfei, Huang Jiali, Gu Fen. Application effect and safety analysis of a sputum splash prevention device [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(3): 225-229.
[12]	Wu Shaozhu, Yu Xueying, Luo Yuanrong, Liu Yanfei, Ke Caixia. The effectiveness of multidisciplinary graded collaborative management on swallowing screening and intervention in patients with chronic obstructive pulmonary disease [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(3): 230-235.
[13]	Zhang Yidan, Gu Fen, Li Nannan. Current status and nursing research progress of long-term oxygen therapy for patients with chronic obstructive pulmonary disease [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(3): 249-253.
[14]	Qu Chunjin, Peng Jiayi, Liu Xinyi, Xiao Guanchen, Gu Fen, Li Nannan. Research progress on continuous nursing of patients with chronic obstructive pulmonary disease [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(3): 254-259.
[15]	Xu Siyun, Lu Nihong. Research progress of respiratory system injury caused by novel coronavirus [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(3): 267-272.